Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07814014
Recruiting Observational

Real-world Insight Into Systemic Therapies for HCC: Single-center Study

NCT07814014 · tracked via the Priya Life Science Egypt tracker
Sponsor
Mansoura University
Phase
Observational
Started
2026-08-01
Last updated
2026-09-10

Condition(s) studied

HCC - Hepatocellular Carcinoma

Study summary

Real-world data from a single-center experience evaluating patients with hepatocellular carcinoma (HCC) receiving systemic therapies

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patient with HCC * Child-Pugh class A, B7 * Performance state 0-1 (Eastern Cooperative Oncology Group (ECOG scale). * Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B with diffuse, infiltrative or extensive bilobar involvement or BCLC stage B with tumor progression after TACE. Exclusion Criteria: * patient with other tumor than HCC * Child-Turcotte-Pugh score B (8,9) and C. * Patients eligible for treatment other than systemic therapy according to Barcelona Clinic liver cancer.

Primary outcome measure(s)

  • overall survival (OS) — 1 year
    time from initiation of systemic therapy to death from any cause
  • treatment response — 1 year
    m-RESIST analysis of the patients as its categories * CR - Complete response Disappearance of all arterial enhancement in all target lesions * PR - Partial response ≥30% decrease in the sum of diameters of viable tumor * SD - Stable disease Neither sufficient decrease for PR nor sufficient increase for PD * PD - Progressive disease ≥20% increase in the sum of viable tumor diameters, with an absolute increase of ≥5 mm, or appearance of new lesions/other progression criteria
  • progression free survival (PFS) — one year
    time from initiation of systemic therapy to radiological diseasas progression or death from any cause , whichever occur first

Trial sites (1)

FacilityCityRegionStatus
Mansoura University Hospitals Al Mansurah Dakahlia Governorate Recruiting

More Mansoura University trials in Egypt

PCNL Versus RIRS for Management of Stones in Solitary Kidney Active, not recruiting
Role of HFNC During FOB in Patients With Respiratory Failure Recruiting
FANS-FURS vs Suction Mini-PCNL for 2-3 cm Renal Stones: A Multicenter Randomized Trial Starting soon
Fully Versus Partially Guided Implants Placement: Measurement of Accuracy of Implant Position and Passivity of Superstructures. Active, not recruiting
Maxillary and Mandibular Nerve Block Recruiting

Other trials for the same condition

Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals Enrolling by invitation
Predictors of HCC in Post-HCV Cirrhotic Patients After SVR Starting soon
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07814014 on ClinicalTrials.gov ↗ ← All trials in Egypt